Wire · opportunities
FDA Accepts SL1009 Resubmission for PDCD, Sets December PDUFA Date
◆ Sectors
Biotech
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 1 September 2026 · Fusion42 review
The FDA has accepted the complete Class 2 resubmission of SL1009 for treating a rare, life-threatening primary progressive cerebellar ataxia (PDCD) and set a PDUFA date for December 30, 2026, despite Phase 3 trial challenges.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You must prepare regulatory and market strategies for a narrow window before December 30 to capitalise on the rare disease space opening. Your clinical and commercial planning needs fresh urgency around this rare neurodegenerative condition.
◆ Coverage
1 source · 4 Aug 2026
◆ Related on Wire
◆ Topics
BiotechFDAdrug-resubmissionrare-diseaseclinical-trialsPDUFA-date